Over the years, life sciences, ranging from biotechnology to pharmaceuticals, consolidated as the third economic activity in Catalonia, have become one of the pillars for building a new economic model that distances us from the low-wage formula. In essence, it is about promoting activities that generate a lot of added value or, more precisely, much more value per worker. In short, economic activities that allow productivity to increase. An outstanding subject, although there are signs of improvement, as indicated by the Economic Report of Catalonia 2025, a study prepared by the Catalan Chambers of Commerce.

The Catalan biopharmaceutical Ona Therapeutics has closed a Series B funding round of 74.2 million euros to continue developing its cancer treatments. The new capital injection has been co-led by Valencian investor Columbus Venture Partners and French manager Mérieux Equity Partners, in addition to the public Cofides and the family office Korys. Current partners also participated: Asabys Partners, Alta Life Sciences, Bpifrance, CDTI, FundPlus NV, and Ysios Capital.